The Readout LOUD

Listen: Democratizing CRISPR, drugging the undruggable, and reading pharma’s fine print

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Cheaper insulin, the next Juul, and diagnosing disease with sound

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: The fate of Bristol-Myers-Celgene, the tragedy of SIDS, and health tech’s unforeseen challenge

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Another big Alzheimer’s failure, postpartum progress, and Long Island shores

By Rebecca Robbins, Adam Feuerstein, and Matthew Herper

The Readout LOUD

Listen: How startups stop, the new FDA boss, and Theranos on the big screen

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Every conceivable angle of Scott Gottlieb’s FDA resignation

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: CEOs at the Senate, merger mania, and sleuthing startups

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: A big scoop on opioid marketing

By Rebecca Robbins, Adam Feuerstein, and Andrew Joseph

The Readout LOUD

Listen: Painkiller racketeering, the limits of genetic tests, and pharma’s day on the Hill

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: The AI hype machine, ketamine’s future, and the rocky path ahead for NASH

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: A bad day for bold biotech, campaign 2020, and where do drugs come from?

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Another Alzheimer’s setback, crypto for biotech, and a blessing of unicorns

By Damian Garde and Rebecca Robbins

The Readout LOUD

Listen: CRISPR upheaval, Celgene’s chutzpah, and canine genomics

By Damian Garde and Rebecca Robbins

The Readout LOUD

LISTEN: FDA furloughs, ’80s pop radio, and video game therapeutics

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: A people’s history of J.P. Morgan

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Watson’s latest stumble, a glimpse into the crystal ball, and revisiting Sarepta

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Gilead’s new boss, the year that was, and the thing about DNA tests

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Using the word ‘cure,’ an FDA loophole, & making biotech history

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Your guide to the #CRISPRbabies controversy

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: What the midterms mean, a golden age on hold, and the $4 million drug

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Biotech’s October surprise, the precise cost of precision, and breaking postpartum silence

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Pharma at the ballot box, the latest Alzheimer’s argument, and truly personalized medicine

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: Drug pricing partisanship, tech’s march into health care, and Tinder for clinical trials

Listen: Pharma felonies, cardiac CRISPR, and a strange day at the FDA

Listen: Boardroom drama, whiskey-fueled science, & millionaires on mushrooms

Listen: When scientists get mad online, for-profit cancer care, & the perils of naming a startup

Listen: Democratizing CRISPR, drugging the undruggable, and reading pharma’s fine print

Listen: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst

Listen: Cheaper insulin, the next Juul, and diagnosing disease with sound

Listen: The fate of Bristol-Myers-Celgene, the tragedy of SIDS, and health tech’s unforeseen challenge

Listen: Another big Alzheimer’s failure, postpartum progress, and Long Island shores

Listen: How startups stop, the new FDA boss, and Theranos on the big screen

Listen: Every conceivable angle of Scott Gottlieb’s FDA resignation

Listen: CEOs at the Senate, merger mania, and sleuthing startups

Listen: A big scoop on opioid marketing

Listen: Painkiller racketeering, the limits of genetic tests, and pharma’s day on the Hill

Listen: The AI hype machine, ketamine’s future, and the rocky path ahead for NASH

Listen: A bad day for bold biotech, campaign 2020, and where do drugs come from?

Listen: Another Alzheimer’s setback, crypto for biotech, and a blessing of unicorns

Listen: CRISPR upheaval, Celgene’s chutzpah, and canine genomics

LISTEN: FDA furloughs, ’80s pop radio, and video game therapeutics

LISTEN: A people’s history of J.P. Morgan

LISTEN: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring

LISTEN: Watson’s latest stumble, a glimpse into the crystal ball, and revisiting Sarepta

LISTEN: Gilead’s new boss, the year that was, and the thing about DNA tests

LISTEN: Using the word ‘cure,’ an FDA loophole, & making biotech history

LISTEN: Your guide to the #CRISPRbabies controversy

LISTEN: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts

LISTEN: What the midterms mean, a golden age on hold, and the $4 million drug

LISTEN: Biotech’s October surprise, the precise cost of precision, and breaking postpartum silence

LISTEN: Pharma at the ballot box, the latest Alzheimer’s argument, and truly personalized medicine